1. Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF)
- Author
-
Jan Benes, Martin Kotrc, Katerina Kroupova, Peter Wohlfahrt, Jan Kovar, Janka Franekova, Marketa Hegarova, Lenka Hoskova, Eva Hoskova, Terezie Pelikanova, Petr Jarolim, Josef Kautzner, and Vojtech Melenovsky
- Subjects
Medicine ,Science - Abstract
Abstract The role of metformin (MET) in the treatment of patients with advanced HFrEF and type 2 diabetes mellitus (DM) is not firmly established. We studied the impact of MET on metabolic profile, quality of life (QoL) and survival in these patients. A total of 847 stable patients with advanced HFrEF (57.4 ± 11.3 years, 67.7% NYHA III/IV, LVEF 23.6 ± 5.8%) underwent clinical and laboratory evaluation and were prospectively followed for a median of 1126 (IQRs 410; 1781) days for occurrence of death, urgent heart transplantation or mechanical circulatory support implantation. A subgroup of 380 patients (44.9%) had DM, 87 of DM patients (22.9%) were treated with MET. Despite worse insulin sensitivity and more severe DM (higher BMI, HbA1c, worse insulin resistance), MET-treated patients exhibited more stable HF marked by lower BNP level (400 vs. 642 ng/l), better LV and RV function, lower mitral and tricuspid regurgitation severity, were using smaller doses of diuretics (all p
- Published
- 2022
- Full Text
- View/download PDF